Filing Flows › Aurinia Pharmaceuticals (AUPH) › Guidance history
Aurinia Pharmaceuticals (AUPH) guidance history: what it guided and what it reported
Aurinia Pharmaceuticals gave guidance in 8 earnings releases on file since Feb 27, 2025. Of 1 guided period since reported, it met or beat its own guidance once (100%). Revenue: 1 of 1, on average +2.0% against the guided midpoint. Its releases raised guidance 3 times and lowered it 0 times.
Revenue
Met or beat 1 of 1 periods (1 above, 0 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $315M–$325M (Feb 26, 2026) → reaffirmed $315M–$325M (May 7, 2026) → reaffirmed $315M–$325M (Aug 6, 2026) → raised $325M–$330M (Oct 30, 2026) | — | to be reported | — |
| FY2025 | $250M–$260M (Feb 27, 2025) → reaffirmed $250M–$260M (May 12, 2025) → raised $260M–$270M (Jul 31, 2025) → raised $275M–$280M (Nov 4, 2025) | $283M | above the range | +2.0% |
The latest quarter
Aurinia Pharmaceuticals, Q3 2026: revenue $83.7M (+14% year over year), operating margin 42.3%, net earnings $31.7M, operating cash flow $46.4M. The chart follows the revenue to costs, profit and cash.
Questions
Does Aurinia Pharmaceuticals beat its guidance?
Aurinia Pharmaceuticals gave guidance in 8 earnings releases on file since Feb 27, 2025. Of 1 guided period since reported, it met or beat its own guidance once (100%). Revenue: 1 of 1, on average +2.0% against the guided midpoint.
How often does Aurinia Pharmaceuticals raise guidance?
Its earnings releases raised guidance 3 times and lowered it 0 times since Feb 27, 2025.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.